Oric Pharmaceuticals announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, CA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ORIC:
- Oric Pharmaceuticals price target raised to $16 from $13 at H.C. Wainwright
- Oric Pharmaceuticals price target raised to $17 from $14 at JPMorgan
- Oric Pharmaceuticals price target raised to $15 from $13 at Citi
- Oric announces initial data from ongoing ORIC-114 Phase 1 dose escalation
- Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile